The standard management of advanced-stage ovarian cancer has been a subject of debate, and much controversy remains as to whether patients should have primary cytoreductive surgery followed by chemotherapy or neoadjuvant chemotherapy followed by interval cytoreductive surgery. In addition, there is increasing evidence that the patients who ultimately gain the most benefit from surgery are those with no residual disease at the completion of surgery (R0 resection). Therefore, to determine the best therapeutic strategy (primary cytoreductive surgery vs. neoadjuvant chemotherapy) for an individual patient, it is critically important to estimate the likelihood that primary cytoreductive surgery will leave no macroscopic residual disease. A number of studies have evaluated the use of serologic markers, such as CA-125, and imaging modalities, such as computed tomography (CT) or positron emission tomography/CT (PET/CT), to determine which patients are ideal candidates for primary cytoreductive surgery. More recently, laparoscopy has been proposed as a reliable predictor of R0 resection. In this report, we provide a review of the existing literature on the proposed criteria to predict the outcome of cytoreductive surgery and the role of laparoscopy-based scores in the management of advanced ovarian cancer.

h i g h l i g h t s SLN mapping was independently associated with significantly lower rate of patient-reported lower extremity lymphedema (LEL). Increasing BMI and use of adjuvant EBRT were associated with an increased prevalence of patient-reported LEL. SLN mapping in the surgical management of newly diagnosed endometrial cancer may spare these patients from LEL. Survival outcomes were similar between SLN mapping and comprehensive lymphadenectomy after endometrial cancer surgery.

No abstract

No abstract

No abstract